ProShare Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-14,285
| Closed | -$2.46M | – | 2370 |
|
|
2021
Q3 | $2.46M | Buy |
14,285
+1,470
| +11% | +$192K | 0.01% | 676 |
|
|
2021
Q2 | $1.61M | Buy |
12,815
+3,447
| +37% | +$435K | ﹤0.01% | 798 |
|
|
2021
Q1 | $1.27M | Sell |
9,368
-872
| -9% | -$113K | ﹤0.01% | 865 |
|
|
2020
Q4 | $1.31M | Sell |
10,240
-313
| -3% | -$36.7K | ﹤0.01% | 774 |
|
|
2020
Q3 | $1.19M | Buy |
10,553
+1,951
| +23% | +$194K | 0.01% | 677 |
|
|
2020
Q2 | $820K | Sell |
8,602
-1,334
| -13% | -$129K | ﹤0.01% | 771 |
|
|
2020
Q1 | $893K | Sell |
9,936
-7,647
| -43% | -$594K | 0.01% | 615 |
|
|
2019
Q4 | $932K | Sell |
17,583
-1,848
| -10% | -$84.3K | ﹤0.01% | 818 |
|
|
2019
Q3 | $768K | Sell |
19,431
-563
| -3% | -$24.4K | ﹤0.01% | 841 |
|
|
2019
Q2 | $821K | Sell |
19,994
-2,297
| -10% | -$95.1K | ﹤0.01% | 835 |
|
|
2019
Q1 | $1.04M | Buy |
22,291
+2,557
| +13% | +$112K | 0.01% | 742 |
|
|
2018
Q4 | $859K | Sell |
19,734
-3,761
| -16% | -$188K | 0.01% | 753 |
|
|
2018
Q3 | $1.34M | Sell |
23,495
-838
| -3% | -$41.2K | 0.01% | 703 |
|
|
2018
Q2 | $1.18M | Sell |
24,333
-1,466
| -6% | -$53.4K | 0.01% | 769 |
|
|
2018
Q1 | $1.01M | Sell |
25,799
-4,142
| -14% | -$176K | 0.01% | 811 |
|
|
2017
Q4 | $1.27M | Buy |
29,941
+5,952
| +25% | +$223K | 0.01% | 752 |
|
|
2017
Q3 | $895K | Buy |
23,989
+1,334
| +6% | +$46.3K | 0.01% | 766 |
|
|
2017
Q2 | $688K | Sell |
22,655
-646
| -3% | -$18.7K | 0.01% | 844 |
|
|
2017
Q1 | $617K | Sell |
23,301
-6,038
| -21% | -$159K | 0.01% | 935 |
|
|
2016
Q4 | $749K | Buy |
29,339
+2,428
| +9% | +$76.9K | 0.01% | 901 |
|
|
2016
Q3 | $974K | Sell |
26,911
-4,146
| -13% | -$137K | 0.01% | 687 |
|
|
2016
Q2 | $1.05M | Buy |
31,057
+604
| +2% | +$19.6K | 0.01% | 698 |
|
|
2016
Q1 | $804K | Buy |
30,453
+547
| +2% | +$15.9K | 0.01% | 791 |
|
|
2015
Q4 | $1.46M | Buy |
29,906
+2,619
| +10% | +$94.2K | 0.02% | 608 |
|
|
2015
Q3 | $679K | Sell |
27,287
-1,670
| -6% | -$50.2K | 0.01% | 823 |
|
|
2015
Q2 | $916K | Sell |
28,957
-205
| -0.7% | -$6.62K | 0.01% | 818 |
|
|
2015
Q1 | $1.11M | Buy |
29,162
+4,269
| +17% | +$170K | 0.01% | 795 |
|
|
2014
Q4 | $970K | Buy |
+24,893
| New | +$868K | 0.01% | 871 |
|
|
2014
Q3 | – | Sell |
-8,017
| Closed | -$272K | – | 2392 |
|
|
2014
Q2 | $272K | Buy |
8,017
+827
| +12% | +$27.7K | ﹤0.01% | 1970 |
|
|
2014
Q1 | $248K | Buy |
+7,190
| New | +$324K | ﹤0.01% | 2369 |
|
ProShare Advisors's XLRN Position: Q4 2021 in Review
ProShare Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 14,285 shares — an estimated $2.46M sold.
ProShare Advisors first reported a position in XLRN in Q1 2014 and held it in 30 quarters. The position peaked at $2.46M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- ProShare Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- ProShare Advisors sold 14,285 Acceleron Pharma shares in Q4 2021, an estimated $2.46M.
- ProShare Advisors first reported a position in Acceleron Pharma in Q1 2014 and held it in 30 quarters.
- ProShare Advisors's Acceleron Pharma position peaked at $2.46M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.